About Jazz Pharmaceuticals plc
https://www.jazzpharma.comJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
CEO
Renee D. Gala
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 271
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B of A Securities
Buy
Goldman Sachs
Buy
Truist Securities
Buy
Needham
Buy
HC Wainwright & Co.
Buy
Baird
Outperform
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.15M
Value:$1.05B
VANGUARD GROUP INC
Shares:5.91M
Value:$1.01B
BLACKROCK, INC.
Shares:5.56M
Value:$949.59M
Summary
Showing Top 3 of 684
About Jazz Pharmaceuticals plc
https://www.jazzpharma.comJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.13B ▲ | $810.84M ▼ | $251.41M ▲ | 22.33% ▲ | $4.14 ▲ | $235.86M ▲ |
| Q2-2025 | $1.05B ▲ | $1.62B ▲ | $-718.47M ▼ | -68.71% ▼ | $-11.74 ▼ | $-514.18M ▼ |
| Q1-2025 | $897.84M ▼ | $849.11M ▲ | $-92.54M ▼ | -10.31% ▼ | $-1.52 ▼ | $138.86M ▼ |
| Q4-2024 | $1.09B ▲ | $768.69M ▲ | $191.12M ▼ | 17.56% ▼ | $3.16 ▼ | $396.98M ▼ |
| Q3-2024 | $1.05B | $683.15M | $215.06M | 20.38% | $3.5 | $425.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.05B ▲ | $11.36B ▲ | $7.4B ▲ | $3.96B ▲ |
| Q2-2025 | $1.67B ▼ | $10.94B ▼ | $7.24B ▼ | $3.71B ▼ |
| Q1-2025 | $2.57B ▼ | $11.53B ▼ | $7.36B ▼ | $4.17B ▲ |
| Q4-2024 | $2.99B ▲ | $12.01B ▼ | $7.92B ▼ | $4.09B ▼ |
| Q3-2024 | $2.62B | $12.26B | $8.08B | $4.17B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $251.41M ▲ | $474.62M ▲ | $-327.8M ▲ | $-10.83M ▲ | $46.19M ▲ | $459.44M ▲ |
| Q2-2025 | $-718.47M ▼ | $88.86M ▼ | $-641.02M ▼ | $-124.53M ▲ | $-672.07M ▼ | $100.89M ▼ |
| Q1-2025 | $-92.54M ▼ | $429.78M ▲ | $-168.93M ▲ | $-813.47M ▼ | $-550.92M ▼ | $390.9M ▲ |
| Q4-2024 | $191.12M ▼ | $398.58M ▼ | $-193.29M ▼ | $-8.28M ▼ | $234.73M ▼ | $385.29M ▼ |
| Q3-2024 | $215.06M | $398.75M | $214.09M | $246.43M | $862.33M | $387.96M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 DefitelioDefibrotide | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ | $40.00M ▼ |
 EpidiolexEpidyolex | $280.00M ▲ | $250.00M ▼ | $300.00M ▲ | $220.00M ▼ |
 High Sodium AG Oxybate Product Royalty Revenue | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ | $50.00M ▲ |
 Other Products | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Royalty And Contract Revenues | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 RylazeEnrylaze | $100.00M ▲ | $100.00M ▲ | $100.00M ▲ | $90.00M ▼ |
 Sativex | $10.00M ▲ | $0 ▼ | $0 ▲ | $10.00M ▲ |
 Vyxeos | $50.00M ▲ | $40.00M ▼ | $40.00M ▲ | $30.00M ▼ |
 Xyrem | $50.00M ▲ | $40.00M ▼ | $40.00M ▲ | $40.00M ▲ |
 Xywav | $400.00M ▲ | $420.00M ▲ | $430.00M ▲ | $340.00M ▼ |
 Zepzelca | $80.00M ▲ | $70.00M ▼ | $80.00M ▲ | $60.00M ▼ |
 Ziihera | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe | $80.00M ▲ | $90.00M ▲ | $80.00M ▼ | $80.00M ▲ |
 Other Countries | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
 UNITED STATES | $970.00M ▲ | $1.02Bn ▲ | $800.00M ▼ | $940.00M ▲ |
CEO
Renee D. Gala
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 271
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B of A Securities
Buy
Goldman Sachs
Buy
Truist Securities
Buy
Needham
Buy
HC Wainwright & Co.
Buy
Baird
Outperform
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.15M
Value:$1.05B
VANGUARD GROUP INC
Shares:5.91M
Value:$1.01B
BLACKROCK, INC.
Shares:5.56M
Value:$949.59M
Summary
Showing Top 3 of 684